Parabilis Medicines IPO: offering terms from its S-1
Parabilis Medicines priced its IPO at $20 a share on 10 Jun 2026 and raised $670 million. Its shares trade on Nasdaq as PBLS.
Headlines
- Net loss, 2025
- $146M
- IPO price
- $20
- $670M raised
Parabilis Medicines IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- PBLS
- IPO price
- $20
- Shares offered
- 33,500,000
- Raised
- $670M
- Registered
- $728M, the amount the filing fee is paid on
- Underwriters
- Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities and LifeSci Capital
- First filed
- 19 May 2026
Parabilis Medicines revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$152M | -$146M |
| First quarter of 2026 | - | -$47M | -$45M |
Parabilis Medicines share structure and company facts
- Share classes and votes
- Class A: 1 vote, Class B: 0 votes
- Employees
- 145
- Headquarters
- Cambridge, MA
Parabilis Medicines shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $20
- Priced 10 Jun 2026
- First close
- $31.60
- +58% on the IPO price
- Latest close
- $25.03
- +25% on the IPO price
Parabilis Medicines's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Parabilis Medicines's newest prospectus (424B4 filed 10 Jun 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.